Literature DB >> 19126291

Cancer, chitosan nanoparticles and catalytic nucleic acids.

Mei Lin Tan1, Peter F M Choong, Crispin R Dass.   

Abstract

OBJECTIVES: The aim of this review was to examine gene therapy involving DNAzyme and siRNA encapsulation into chitosan nanoparticles, discussing the current and future status of this drug delivery system in enhancing drug delivery and cancer therapy. KEY
FINDINGS: Cancer is a disease state in which the cells in our body undergo mutations at the genetic level and are transformed, acquiring the ability to replicate limitlessly. Conventional cancer treatment involves the use of surgery and cytotoxic chemotherapy and/or radiotherapy, which have the potential of harming normal, otherwise healthy, non-neoplastic cells. Newer forms of therapy such as immunotherapy and gene therapy have shown initial promise, but still require better ways to limit exposure to cancerous lesions in the body. As a result drug delivery systems have been developed in attempts to deliver therapeutics specifically to the target lesion site. One recent drug delivery system has revolved around the use of chitosan nanoparticle technology, where therapeutics are encapsulated into nanoparticles and targeted to tumours.
SUMMARY: Though few, attempts at encapsulating therapeutics such as deoxyribozymes and small or short interfering RNA have been optimistic and encouraging.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19126291     DOI: 10.1211/jpp/61.01.0002

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  11 in total

1.  Comparative studies on chitosan and polylactic-co-glycolic acid incorporated nanoparticles of low molecular weight heparin.

Authors:  Tianzhi Yang; Divine Nyiawung; Alexandra Silber; Jiukuan Hao; Leanne Lai; Shuhua Bai
Journal:  AAPS PharmSciTech       Date:  2012-09-28       Impact factor: 3.246

Review 2.  Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis.

Authors:  Jayshree Mishra; Joseph Drummond; Sohel H Quazi; Satya Sridhar Karanki; J J Shaw; Ben Chen; Narendra Kumar
Journal:  Crit Rev Oncol Hematol       Date:  2012-10-23       Impact factor: 6.312

Review 3.  Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers.

Authors:  Riccardo A A Muzzarelli
Journal:  Mar Drugs       Date:  2010-02-21       Impact factor: 5.118

Review 4.  Strategies for the targeted delivery of therapeutics for osteosarcoma.

Authors:  Dennis P M Hughes
Journal:  Expert Opin Drug Deliv       Date:  2009-12       Impact factor: 6.648

5.  Poliglusam Nanoparticles Activate T Cell Response in Breast Cancer Cell: an In Vivo and In Vitro Study.

Authors:  Neda Soleimani; Akbar Vaseghi; Valentina Loconte
Journal:  J Fluoresc       Date:  2019-09-06       Impact factor: 2.217

6.  Transfection efficiency of depolymerized chitosan and epidermal growth factor conjugated to chitosan-DNA polyplexes.

Authors:  Sasamon Supaprutsakul; Wilaiwan Chotigeat; Supreya Wanichpakorn; Ureporn Kedjarune-Leggat
Journal:  J Mater Sci Mater Med       Date:  2010-01-26       Impact factor: 3.896

7.  Comparative studies of salinomycin-loaded nanoparticles prepared by nanoprecipitation and single emulsion method.

Authors:  Qin Wang; Puyuan Wu; Wei Ren; Kai Xin; Yang Yang; Chen Xie; Chenchen Yang; Qin Liu; Lixia Yu; Xiqun Jiang; Baorui Liu; Rutain Li; Lifeng Wang
Journal:  Nanoscale Res Lett       Date:  2014-07-15       Impact factor: 4.703

8.  Influence of Chitosan Nanoparticles as the Absorption Enhancers on Salvianolic acid B In vitro and In vivo Evaluation.

Authors:  Xin Jin; Shi-Bing Zhang; Shi-Meng Li; Ke Liang; Zeng-Yong Jia
Journal:  Pharmacogn Mag       Date:  2016 Jan-Mar       Impact factor: 1.085

9.  Biofunctional core-shell polypyrrole-polyethylenimine nanocomplex for a locally sustained photothermal with reactive oxygen species enhanced therapeutic effect against lung cancer.

Authors:  Chih-Wei Chiang; Er-Yuan Chuang
Journal:  Int J Nanomedicine       Date:  2019-02-28

Review 10.  Marine medicinal glycomics.

Authors:  Vitor H Pomin
Journal:  Front Cell Infect Microbiol       Date:  2014-01-29       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.